Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764679 | 0.89 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL17537035 | 0.88 | TSHR (0.47) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL10017868 | 0.86 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL15481191 | 0.85 | EPHX1 (0.49) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL6824699 | 0.83 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2TSHRLMNA | |
| SCHEMBL12368087 | 0.82 | L3MBTL1 (0.48) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL7061424 | 0.81 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL7057167 | 0.81 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2CASP1TSHR | |
| SCHEMBL25054040 | 0.79 | NPC1 (0.47) | RAB9ANPC1SMN1; SMN2CASP1LMNA | |
| SCHEMBL7985754 | 0.79 | EPHX1 (0.46) | RAB9ANPC1SMN1; SMN2CASP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | USV PRIVATE LIMITED (IN) | 2016-03-03 | — | — | US | claimed |
| EP-2978750-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV Limited (IN) | 2016-02-03 | — | — | EP | claimed |
| WO-2014167577-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV LIMITED (IN) | 2014-10-16 | — | — | WO | claimed |
| EP-2978750-B1 | \"SYNTHESIS OF DABIGATRAN\ | USV PRIVATE LTD (IN) | 2020-03-04 | — | — | EP | disclosed |
| US-9688657-B2 | Synthesis of dabigatran | USV PRIVATE LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | USV PRIVATE LIMITED (IN) | 2016-03-03 | — | — | US | disclosed |
| EP-2978750-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV Limited (IN) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014167577-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV LIMITED (IN) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | ESD, F2, PROC | RAB9A 3293/4885NPC1 4734/4885SMN1; SMN2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.